

Product Data Sheet

Product Name: RGX-104 Hydrochloride

Cat. No.: GC19448

Chemical Properties

Cas. No. 610318-03-1

SMILES O=C(O)CC1=CC=CC(OCC[C@H](N(CC2=CC=CC(C(F)(F)F)=C2Cl)CC(C3=CC=CC=C3)C4=CC=CC=C4)C)=C1.Cl


Formula $C_{34}H_{34}Cl_2F_3NO_3$ M.Wt 632.54

Solubility DMSO : ≥ 130 mg/mL (218.09 mM); Water : < 0.1 mg/mL (insoluble) Storage 4°C, protect from light

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

RGX-104 Hydrochloride is an orally active liver X receptor (LXR) agonist that modulates innate

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

immunity by activating the transcription of the apolipoprotein E (ApoE) gene^[1, 2]. Up-regulation of ApoE promotes the clearance of immunosuppressive cells, such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), thereby reversing the immunosuppressive state of the tumor microenvironment and enhancing antitumor immune responses^[3]. RGX-104 Hydrochloride also exhibits antitumor activity and induces cell pyroptosis^[4, 5].

References:

- [1] Tavazoie M F, Pollack I, Tanqueco R, et al. LXR/ApoE activation restricts innate immune suppression in cancer[J]. Cell, 2018, 172(4): 825-840. e18.
- [2] Mita M, Mita A, Chmielowski B, et al. Abstract B001: A phase 1 trial of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies[J]. Molecular Cancer Therapeutics, 2018, 17(1_Supplement): B001-B001.
- [3] Zhang J, Zhu X, Han L, et al. Cholesterol Metabolism-Mediated Immune Regulation and Cancer Immunotherapy[J]. Available at SSRN 4760648.
- [4] Liang H, Shen X. LXR activation radiosensitizes non-small cell lung cancer by restricting myeloid-derived suppressor cells[J]. Biochemical and Biophysical Research Communications, 2020, 528(2): 330-335.
- [5] Qiu W, Su W, Xu J, et al. Immunomodulatory-Photodynamic Nanostimulators for Invoking Pyroptosis to Augment Tumor Immunotherapy[J]. Advanced Healthcare Materials, 2022, 11(21): 2201233.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA